Background {#Sec1}
==========

In 2012, 951,000 new diagnoses of gastric cancer (GC) and 723,000 GC deaths were calculated worldwide, accounting for 6.8% of all cancer incidence and 8.8% of all cancer mortality, respectively \[[@CR1]\]. At present, GC is the second common cancer in China, while approximately 679,100 new cancer cases and 498,000 related deaths were estimated in China in 2015 \[[@CR2]\]. The most promising curative treatment for GC is surgical resection. However, this treatment alone is not enough for curing advanced GC because of poor long-term outcome, thus a multimodality therapy is required. Nowadays, neoadjuvant chemotherapy has been increasingly used to prolong patient survival worldwide \[[@CR3]\], therefore an effective histopathological evaluation method predicting patient prognosis is urgently needed in clinical practice. So far, four tumor regression grading (TRG) systems were presented by several studies. Mandard et al. proposed a five-tiered TRG system in esophageal carcinoma which has been used widely in digestive malignancy \[[@CR4]\]. The Japanese Gastric Cancer Association (JGCA) suggested a different five-tiered grading system specifically for GC \[[@CR5]\]. College of American Pathologists (CAP) recommended a simplified four-tiered grading system based on Mandard-TRG system \[[@CR6]\]. In China, a three-tiered grading system has been used for solid malignancies to evaluate the extent of therapy-related tumor regression \[[@CR7]\]. In recent years, Becker et al. recommended a four-tiered grading system for GC based on large number of patients and long-term follow-up \[[@CR8], [@CR9]\]. For the purpose of further evaluation of the relationship between TRG and prognosis, we retrospectively collected 192 patients in our hospital. We used the above five TRG systems to assess the pathological response respectively, trying to select a better histopathological evaluation system.

Methods {#Sec2}
=======

Patients {#Sec3}
--------

Between January 2007 and August 2013, 192 patients with locally advanced gastric adenocarcinoma (including adenocarcinoma of the esophagogastric junction) underwent gastrectomy in National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College. All the patients received neoadjuvant chemotherapy previously. The treatment strategies were not uniform, and the drugs most used included oxaliplatin, cisplatin, docetaxel, 5-fluorouracil and Tegafur Gimeracil Oteracil Potassium Capsule. There were 133 patients who received additional adjuvant chemotherapy after surgery. All cases had only one primary gastric tumor, except one patient, who had two primary lesions located at the fundus and antrum, separately. The tumor located at the fundus was evaluated in our study for its relatively higher T category. There were 139 male and 53 female, and the age ranged 31--77 years old (median age, 55 years old).

Follow-up {#Sec4}
---------

The mortality data was mainly gathered from clinical archives, or via telephone and mail. After treatment, patients were evaluated every 3 months for the first 2 years, and subsequently every 6 months for the following 3 years, and then annually according to institutional policy. Information of recurrence was updated every time the patients came for follow-up visits. The time of overall-survival (OS) was calculated from the first day of the neoadjuvant chemotherapy to the day when death occurred or to the last follow-up (September 2015). The time of progression-free-survival (PFS) was calculated from the first day of the neoadjuvant chemotherapy to the day when progression happened, death occurred or to the last follow-up (September 2015). Eleven patients were lost to follow-up. The median follow-up time was 31 months (4.1--95.3 months). Three patients, who died as the result of surgery complications, and 8 patients, whose follow-up time after surgery were less than 3 months, were excluded from the survival analysis.

Assessment of the specimens {#Sec5}
---------------------------

If obvious residual carcinoma was identified macroscopically, the tumor specimen was sampled for at least 1 block per centimeter. If the maximum of residue was less than 3 cm or only areas of scar existed, the whole suspected lesion was submitted completely for histological examination. Four-micrometer sections were stained with hematoxylin and eosin. The average of slides per residual tumor was 9.7 (3--77), while the median number of the examined lymph nodes per case was 24 (3--58).

Clinicopathological characteristics {#Sec6}
-----------------------------------

The clinicopathological features include tumor location, tumor size, histological differentiation, Laurén classification, lymph-vascular invasion (LVI) and perineural invasion (PNI). The tumor staging was based on the American Joint Committee on Cancer (AJCC) cancer staging 7th edition \[[@CR10]\]. All the slides were reviewed by three experienced pathologists (YZ, JY and LX). In case of a disagreement about diagnosis, three pathologists reviewed the slides on a multi-headed microscope and reached a consensus diagnosis.

Tumor regression grading systems {#Sec7}
--------------------------------

The criteria of the five TRG systems are shown in Table [1](#Tab1){ref-type="table"}.Table 1Criteria of five tumor regression grading systemsTRG systemGradeDescriptionMandard-TRG1No residual cancer2Rare residual cancer cells3Fibrosis outgrowing residual cancer4Residual cancer outgrowing fibrosis5Absence of regressive changesJGCA-TRG0No evidence of effect1aViable tumor cells occupy more than 2/3 of the tumorous area1bViable tumor cells remain in more than 1/3 but less than 2/3 of the tumorous area2Viable tumor cells remain in less than 1/3 of the tumorous area3No viable tumor cells remainCAP-TRG0No viable cancer cells (complete response)1Single cells or small groups of cancer cells (moderate response)2Residual cancer outgrown by fibrosis (minimal response)3Minimal or no tumor killed or extensive residual cancer (poor response)China-TRGSevere responseTumor cells completely disappear or very few highly regressive residue exist with obvious scarring and varying inflammationModerate responseMost tumor cells degenerate and necrosis with obvious stroma fibrosis and inflammationMild responseAbsence of or slight necrosis and degeneration of tumor cells accompanied by mild stroma fibrosis and inflammationBecker-TRG1aNo residual tumor/tumor bed1b\<10% residual tumor/tumor bed210--50% residual tumor/tumor bed3\>50% residual tumor/tumor bed

Statistical analysis {#Sec8}
--------------------

Correlations between tumor regression evaluation systems and clinicopathological characteristics were performed by χ2 tests. And 2-sided *p*-values \< 0.05 were considered statistically significant. The survival curve and median survival time were calculated using Kaplan-Meier method and log rank test. The univariate analysis of survival was evaluated by univariate Cox regression analysis. The statistic significant factors in univariate analysis were assessed by backward stepwise multivariate Cox regression analysis. Variables with a *p*-value of \<0.05 were retained, and variables with a p-value of \>0.10 were removed. All statistics were performed by SPSS 16.0 software (SPSS Inc, Chicago, IL).

Results {#Sec9}
=======

Clinicopathological characteristics {#Sec10}
-----------------------------------

All the 192 patients received radical surgery. Forty-nine patients underwent proximal subtotal gastrectomy. Eighty-eight patients underwent distal subtotal gastrectomy. Fifty-three patients underwent total gastrectomy. Two patients underwent residual gastrectomy, both of which underwent distal gastrectomy previously due to severe ulcer. Sixty-three patients underwent D1 lymphadenectomy and 129 underwent D2 lymphadenectomy. The examined numbers of the removed lymph nodes per case ranged from 3 to 58. One-hundred and fifty-nine patients got R0 resection (82.8%). Twenty-one patients had local unresectable residues detected macroscopically by the surgeons while 12 had microscopically positive margins. Forty-four patients had adenocarcinoma of the esophagogastric junction (22.9%), 71 had tumors located at proximal stomach (37.0%), while 77 had tumors located at distal stomach (40.1%). We used maximal diameter of residual tumor/tumor bed to describe the size of tumor, which was divided into three groups \[[@CR8]\]: \<4.5 cm (*n* = 108, 56.3%), 4.5--8 cm (*n* = 64, 33.3%) and \>8 cm (*n* = 20, 10.4%). The clinicopathological characteristics were tabulated in Tables [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}, [4](#Tab4){ref-type="table"}, [5](#Tab5){ref-type="table"} and [6](#Tab6){ref-type="table"}.Table 2Relationships between clinicopathological characteristics and pathological response evaluated by Mandard-TRG systemCharacteristicsTotal cases (*n* = 192), no. (%)Mandard-TRG*P* value1 (*n* = 11), no. (%)2 (*n* = 23), no. (%)3 (*n* = 40), no. (%)4 (*n* = 78), no. (%)5 (*n* = 40), no. (%)Gender0.039 Male139 (72.4)10 (7.2)20 (14.4)29 (20.9)48 (34.5)32 (23) Female53 (27.6)1 (1.9)3 (5.7)11 (20.8)30 (56.6)8 (15.1)Age0.867 \< 55y89 (46.4)6 (6.7)10 (11.2)17 (19.1)39 (43.8)17 (19.1) ≥ 55y103 (53.6)5 (4.9)13 (12.6)23 (22.3)39 (37.9)23 (22.3)Location0.351 Esophagogastric junction44 (22.9)1 (2.3)4 (9.1)8 (18.2)20 (45.5)11 (25) Proximal gastric71 (37)7 (9.9)8 (11.3)15 (21.1)23 (32.4)18 (25.4) Distal gastric77 (40.1)3 (3.9)11 (14.3)17 (22.1)35 (45.5)11 (14.3)Maximal diameter of tumor bed0.004 \< 4.5 cm108 (56.2)9 (8.3)20 (18.5)20 (18.5)44 (40.7)15 (13.9) 4.5--8 cm64 (33.3)1 (1.6)3 (4.7)17 (26.6)27 (42.2)16 (25) \> 8 cm20 (10.4)1 (5)0 (0)3 (15)7 (35)9 (45)Histological differentiation0.003 Well-moderate45 (23.4)4 (8.9)12 (26.7)9 (20)16 (35.6)4 (8.9) Poor147 (76.6)7 (4.8)11 (7.5)31 (21.1)62 (42.2)36 (24.5)Laurén classification0.240 Intestinal77 (40.1)4 (5.2)14 (18.2)14 (19.2)28 (36.4)15 (19.5) Diffuse73 (38)7 (9.6)5 (6.8)10 (23.8)33 (45.2)14 (19.2) Mixed42 (21.9)0 (0)4 (9.5)15 (35.7)17 (40.5)11 (26.2)LVI\<0.001 Negative94 (49)11 (11.7)19 (20.2)28 (29.8)26 (27.7)10 (10.6) Positive98 (51)0 (0)4 (4.1)12 (12.2)52 (53.1)30 (30.6)PNI\<0.001 Negative76 (39.6)11 (14.5)22 (28.9)13 (17.1)23 (30.3)7 (9.2) Positive116 (60.4)0 (0)1 (0.9)27 (23.3)55 (47.4)33 (28.4)AJCC ypT category\<0.001 011 (5.7)11 (100)0 (0)0 (0)0 (0)0 (0) 120 (10.4)0 (0)12 (60)5 (25)3 (15)0 (0) 223 (12)0 (0)5 (21.7)6 (26.1)12 (52.2)0 (0) 357 (29.7)0 (0)5 (8.8)18 (31.6)25 (43.9)9 (15.8) 481 (42.2)0 (0)1 (1.2)11 (13.6)38 (46.9)31 (38.3)AJCC ypN category\<0.001 055 (28.6)9 (16.4)13 (23.6)17 (30.9)10 (18.2)6 (10.9) 136 (18.8)0 (0)6 (16.7)7 (19.4)16 (44.4)7 (19.4) 250 (26)0 (0)3 (6)10 (20)32 (64)5 (10) 351 (26.6)2 (3.9)1 (2)6 (11.8)20 (39.2)22 (43.1)AJCC stage\<0.001 09 (4.7)9 (100)0 (0)0 (0)0 (0)0 (0) 124 (12.5)0 (0)14 (58.3)7 (29.2)2 (8.3)1 (4.2) 253 (27.6)2 (3.8)6 (11.3)14 (26.4)21 (39.6)10 (18.9) 3106 (55.2)0 (0)3 (2.8)19 (17.9)55 (51.9)29 (27.4)R0 resection0.185 Yes159 (82.8)11 (6.9)20 (12.6)35 (22)64 (40.3)29 (18.2) No33 (17.2)0 (0)3 (9.1)5 (15.2)14 (42.4)11 (33.3)Adjuvant chemotherapy0.766 Not received59 (30.7)3 (5.1)6 (10.2)10 (16.9)25 (42.4)15 (25.4) Received133 (69.3)8 (6)17 (12.8)30 (22.6)53 (39.8)25 (18.8) Table 3Relationships between clinicopathological characteristics and pathological response evaluated by JGCA-TRG systemCharacteristicsTotal cases (*n* = 192), no. (%)JGCA -TRG*P* value3 (*n* = 11), no. (%)2 (*n* = 63), no. (%)1b (*n* = 45), no. (%)1a (*n* = 33), no. (%)0 (*n* = 40), no. (%)Gender0.097 Male139 (72.4)10 (7.2)48 (34.5)30 (21.6)19 (13.7)32 (23) Female53 (27.6)1 (1.9)15 (28.3)15 (28.3)14 (26.4)8 (15.1)Age0.711 \< 55y89 (46.4)6 (6.7)26 (29.2)24 (27)16 (18)17 (19.1) ≥ 55y103 (53.6)5 (4.9)37 (35.9)21 (20.4)17 (16.5)23 (22.3)Location0.287 Esophagogastric junction44 (22.9)1 (2.3)12 (27.3)10 (22.7)10 (22.7)11 (25) Proximal gastric71 (37)7 (9.9)23 (32.4)15 (21.1)8 (11.3)18 (25.4) Distal gastric77 (40.1)3 (3.9)28 (36.4)20 (26)15 (19.5)11 (14.3)Maximal diameter of tumor bed\<0.001 \< 4.5 cm108 (56.2)9 (8.3)40 (37)27 (25)17 (15.7)15 (13.9) 4.5--8 cm64 (33.3)1 (1.6)21 (32.8)14 (21.9)12 (18.8)16 (25) \> 8 cm20 (10.4)1 (5)2 (10)4 (20)4 (20)9 (45)Histological differentiation0.060 Well-moderate45 (23.4)4 (8.9)21 (46.7)10 (22.2)6 (13.3)4 (8.9) Poor147 (76.6)7 (4.8)42 (28.6)35 (23.8)27 (18.4)36 (24.5)Laurén classification Intestinal77 (40.1)4 (5.2)29 (37.7)18 (23.4)11 (14.3)15 (19.5) Diffuse73 (38)7 (9.6)20 (27.4)16 (21.9)16 (21.9)14 (19.2) Mixed42 (21.9)0 (0)14 (33.3)11 (26.2)6 (14.3)11 (26.2)LVI\<0.001 Negative94 (49)11 (11.7)46 (48.9)19 (20.2)8 (8.5)10 (10.6) Positive98 (51)0 (0)17 (17.3)26 (26.5)25 (25.5)30 (30.6)PNI\<0.001 Negative76 (39.6)11 (14.5)35 (46.1)14 (18.4)9 (11.8)7 (9.2) Positive116 (60.4)0 (0)28 (24.1)31 (26.7)24 (20.7)33 (28.4)AJCC ypT category\<0.001 011 (5.7)11 (100)0 (0)0 (0)0 (0)0 (0) 120 (10.4)0 (0)17 (85)1 (5)2 (10)0 (0) 223 (12)0 (0)11 (47.8)6 (26.1)6 (26.1)0 (0) 357 (29.7)0 (0)24 (42.1)16 (28.1)8 (14)9 (15.8) 481 (42.2)0 (0)11 (13.6)22 (27.2)17 (21)31 (38.3)AJCC ypN category\<0.001 055 (28.6)9 (16.4)30 (54.5)5 (9.1)5 (9.1)6 (10.9) 136 (18.8)0 (0)13 (26)11 (30.6)5 (13.9)7 (19.4) 250 (26)0 (0)13 (26)21 (42)11 (22)5 (10) 351 (26.6)2 (3.9)7 (13.7)8 (15.7)12 (23.5)22 (43.1)AJCC stage\<0.001 09 (4.7)9 (100)0 (0)0 (0)0 (0)0 (0) 124 (12.5)0 (0)21 (87.5)1 (4.2)1 (4.2)1 (4.2) 253 (27.6)2 (3.8)20 (37.7)12 (22.6)9 (17)10 (18.9) 3106 (55.2)0 (0)22 (20.8)32 (30.2)23 (21.7)29 (27.4)R0 resection0.046 Yes159 (82.8)11 (6.9)55 (34.6)40 (25.2)24 (15.1)29 (18.2) No33 (17.2)0 (0)8 (24.2)5 (15.2)9 (27.3)11 (33.3)Adjuvant chemotherapy0.676 Not received59 (30.7)3 (5.1)16 (27.1)13 (22)12 (20.3)15 (25.4) Received133 (69.3)8 (6)47 (35.3)32 (24.1)21 (15.8)25 (18.8) Table 4Relationships between clinicopathological characteristics and pathological response evaluated by CAP-TRG systemCharacteristicsTotal cases (*n* = 192), no. (%)CAP-TRG*P* value0 (*n* = 11), no. (%)1 (*n* = 23), no. (%)2 (*n* = 40), no. (%)3 (*n* = 118), no. (%)Gender0.134 Male139 (72.4)10 (7.2)20 (14.4)29 (20.9)80 (57.6) Female53 (27.6)1 (1.9)3 (5.7)11 (20.8)38 (71.7)Age0.880 \< 55y89 (46.4)6 (6.7)10 (11.2)17 (19.1)56 (62.9) ≥ 55y103 (53.6)5 (4.9)13 (12.6)23 (22.3)62 (60.2)Location0.525 Esophagogastric junction44 (22.9)1 (2.3)4 (9.1)8 (18.2)31 (70.5) Proximal gastric71 (37)7 (9.9)8 (11.3)15 (21.1)41 (57.7) Distal gastric77 (40.1)3 (3.9)11 (14.3)17 (22.1)46 (59.7)Maximal diameter of tumor bed0.013 \< 4.5 cm108 (56.2)9 (8.3)20 (18.5)20 (18.5)59 (54.6) 4.5--8 cm64 (33.3)1 (1.6)3 (4.7)17 (26.6)43 (67.2) \> 8 cm20 (10.4)1 (5)0 (0)3 (15)16 (80)Histological differentiation0.002 Well-moderate45 (23.4)4 (8.9)12 (26.7)9 (20)20 (44.4) Poor147 (76.6)7 (4.8)11 (7.5)31 (21.1)98 (66.7)Laurén classification0.143 Intestinal77 (40.1)4 (5.2)14 (18.2)14 (19.2)47 (64.4) Diffuse73 (38)7 (9.6)5 (6.8)10 (23.8)28 (66.7) Mixed42 (21.9)0 (0)4 (9.5)15 (35.7)23 (54.8)LVI\<0.001 Negative94 (49)11 (11.7)19 (20.2)28 (29.8)36 (38.3) Positive98 (51)0 (0)4 (4.1)12 (12.2)82 (83.7)PNI\<0.001 Negative76 (39.6)11 (14.5)22 (28.9)13 (17.1)30 (39.5) Positive116 (60.4)0 (0)1 (0.9)27 (23.3)88 (75.9)AJCC ypT category\<0.001 011 (5.7)11 (100)0 (0)0 (0)0 (0) 120 (10.4)0 (0)12 (60)5 (25)3 (15) 223 (12)0 (0)5 (21.7)6 (26.1)12 (52.2) 357 (29.7)0 (0)5 (8.8)18 (31.6)34 (59.6) 481 (42.2)0 (0)1 (1.2)11 (13.6)69 (85.2)AJCC ypN category\<0.001 055 (28.6)9 (16.4)13 (23.6)17 (30.9)16 (29.1) 136 (18.8)0 (0)6 (16.7)7 (19.4)23 (63.9) 250 (26)0 (0)3 (6)10 (20)37 (74) 351 (26.6)2 (3.9)1 (2)6 (11.8)42 (82.4)AJCC stage\<0.001 09 (4.7)9 (100)0 (0)0 (0)0 (0) 124 (12.5)0 (0)14 (58.3)7 (29.2)3 (12.5) 253 (27.6)2 (3.8)6 (11.3)14 (26.4)31 (58.5) 3106 (55.2)0 (0)3 (2.8)19 (17.9)84 (79.2)R0 resection0.212 Yes159 (82.8)11 (6.9)20 (12.6)35 (22)93 (58.5) No33 (17.2)0 (0)3 (9.1)5 (15.2)25 (75.8)Adjuvant chemotherapy0.69 Not received59 (30.7)3 (5.1)6 (10.2)10 (16.9)40 (67.8) Received133 (69.3)8 (6)17 (35.3)30 (22.6)78 (58.6) Table 5Relationships between clinicopathological characteristics and pathological response evaluated by China-TRG systemCharacteristicsTotal cases (*n* = 192), no. (%)China-TRG*P* valueSevere response (*n* = 34), no. (%)Moderate response (*n* = 57), no. (%)Mild response (*n* = 101), no. (%)Gender0.063 Male139 (72.4)30 (21.6)41 (29.5)68 (48.9) Female53 (27.6)4 (7.5)16 (30.2)33 (62.3)Age0.820 \< 55y89 (46.4)15 (16.9)25 (28.1)49 (55.1) ≥ 55y103 (53.6)19 (18.4)32 (31.1)52 (50.5)Location0.906 Esophagogastric junction44 (22.9)6 (13.6)14 (31.8)24 (54.5) Proximal gastric71 (37)14 (19.7)22 (31)35 (49.3) Distal gastric77 (40.1)14 (18.2)21 (27.3)42 (54.5)Maximal diameter of tumor bed\<0.001 \< 4.5 cm108 (56.2)28 (25.9)32 (29.6)48 (44.4) 4.5--8 cm64 (33.3)5 (7.8)21 (32.8)38 (59.4) \> 8 cm20 (10.4)1 (5)4 (20)15 (75)Histological differentiation0.001 Well-moderate45 (23.4)16 (35.6)12 (26.7)17 (37.8) Poor147 (76.6)18 (12.2)45 (30.6)84 (57.1)Laurén classification0.264 Intestinal77 (40.1)18 (23.4)22 (28.6)37 (48.1) Diffuse73 (38)13 (17.8)20 (27.4)40 (54.8) Mixed42 (21.9)3 (7.1)15 (35.7)24 (57.1)LVI\<0.001 Negative94 (49)30 (31.9)35 (37.2)29 (30.9) Positive98 (51)4 (4.1)22 (22.4)72 (73.5)PNI\<0.001 Negative76 (39.6)33 (43.4)20 (26.3)23 (30.3) Positive116 (60.4)1 (0.9)37 (31.9)78 (67.2)AJCC ypT category\<0.001 011 (5.7)11 (100)0 (0)0 (0) 120 (10.4)12 (60)5 (25)3 (15) 223 (12)5 (21.7)8 (34.8)10 (43.5) 357 (29.7)5 (8.8)26 (45.6)26 (45.6) 481 (42.2)1 (1.2)18 (22.2)62 (76.5)AJCC ypN category\<0.001 055 (28.6)22 (40)18 (32.7)15 (27.3) 136 (18.8)5 (13.9)12 (33.3)19 (52.8) 250 (26)4 (13.9)19 (38)27 (54) 351 (26.6)3 (5.9)8 (15.7)40 (78.4)AJCC stage\<0.001 09 (4.7)9 (100)0 (0)0 (0) 124 (12.5)14 (58.3)7 (29.2)3 (12.5) 253 (27.6)7 (13.2)17 (32.1)29 (54.7) 3106 (55.2)4 (3.8)33 (31.1)69 (65.1)R0 resection0.1 Yes159 (82.8)31 (19.5)49 (30.8)79 (49.7) No33 (17.2)3 (9.1)7 (21.2)23 (69.7)Adjuvant chemotherapy0.975 Not received59 (30.7)10 (16.9)17 (28.8)32 (54.2) Received133 (69.3)24 (18)39 (29.3)70 (52.6) Table 6Relationships between clinicopathological characteristics and pathological response evaluated by Becker-TRG systemCharacteristicsTotal cases (*n* = 192), no. (%)Becker-TRG*P* value1a (*n* = 11), no. (%)1b (*n* = 23), no. (%)2 (*n* = 67), no. (%)3 (*n* = 91), no. (%)Gender0.142 Male139 (72.4)10 (7.2)20 (14.4)45 (32.4)64 (46) Female53 (27.6)1 (1.9)3 (5.7)22 (41.5)27 (50.9)Age0.945 \< 55y89 (46.4)6 (6.7)10 (11.2)31 (34.8)42 (47.2) ≥ 55y103 (53.6)5 (4.9)13 (12.6)36 (35)49 (47.6)Location0.562 Esophagogastric junction44 (22.9)1 (2.3)4 (9.1)15 (34.1)24 (54.5) Proximal gastric71 (37)7 (9.9)8 (11.3)24 (33.8)32 (45.1) Distal gastric77 (40.1)3 (3.9)11 (14.3)28 (36.4)35 (45.5)Maximal diameter of tumor bed0.003 \< 4.5 cm108 (56.2)9 (8.3)20 (18.5)35 (32.4)44 (40.7) 4.5--8 cm64 (33.3)1 (1.6)3 (4.7)28 (43.8)32 (50) \> 8 cm20 (10.4)1 (5)0 (0)4 (20)15 (75)Histological differentiation0.003 Well-moderate45 (23.4)4 (8.9)12 (26.7)14 (31.1)15 (33.3) Poor147 (76.6)7 (4.8)11 (7.5)53 (36.1)76 (51.7)Laurén classification0.127 Intestinal77 (40.1)4 (5.2)14 (18.2)25 (32.5)34 (44.2) Diffuse73 (38)7 (9.6)5 (6.8)24 (32.9)37 (50.7) Mixed42 (21.9)0 (0)4 (9.5)18 (42.9)20 (47.6)LVI\<0.001 Negative94 (49)11 (11.7)19 (20.2)39 (41.5)25 (26.6) Positive98 (51)0 (0)4 (4.1)28 (28.6)66 (67.3)PNI\<0.001 Negative76 (39.6)11 (14.5)22 (28.9)22 (28.9)21 (27.6) Positive116 (60.4)0 (0)1 (0.9)45 (38.8)70 (60.3)AJCC ypT category\<0.001 011 (5.7)11 (100)0 (0)0 (0)0 (0) 120 (10.4)0 (0)12 (60)5 (25)3 (15) 223 (12)0 (0)5 (21.7)10 (43.5)8 (34.8) 357 (29.7)0 (0)5 (8.8)29 (50.9)23 (40.4) 481 (42.2)0 (0)1 (1.2)23 (28.4)57 (70.4)AJCC ypN category\<0.001 055 (28.6)9 (16.4)13 (23.6)19 (34.5)14 (25.5) 136 (18.8)0 (0)6 (16.7)16 (44.4)14 (38.9) 250 (26)0 (0)3 (6)21 (42)26 (52) 351 (26.6)2 (3.9)1 (2)11 (21.6)37 (72.5)AJCC stage\<0.001 09 (4.7)9 (100)0 (0)0 (0)0 (0) 124 (12.5)0 (0)14 (58.3)7 (29.2)3 (12.5) 253 (27.6)2 (3.8)6 (11.3)21 (39.6)24 (45.3) 3106 (55.2)0 (0)3 (2.8)39 (36.8)64 (60.4)R0 resection0.234 Yes159 (82.8)11 (6.9)20 (12.6)57 (35.8)71 (44.7) No33 (17.2)0 (0)3 (9.1)10 (30.3)20 (60.6)Adjuvant chemotherapy0.912 Not received59 (30.7)3 (5.1)6 (10.2)20 (33.9)30 (50.8) Received133 (69.3)8 (6)17 (35.3)47 (35.3)61 (45.9)

Tumor regression assessment {#Sec11}
---------------------------

We assessed 192 patients using the five TRG systems respectively. According to Mandard-TRG system, there were 11 patients in grade 1, 23 in grade 2, 40 in grade 3, 78 in grade 4, and 40 in grade 5. According to JGCA-TRG system, there were 11 patients in grade 3, 63 in grade 2, 45 in grade 1b, 33 in grade 1a, and 40 in grade 0. According to CAP-TRG system, there were 11 patients in grade 0, 23 patients in grade 1, 40 patients in grade 2, and 118 patients in grade 3. According to China-TRG system, there were 34 patients in severe response grade, 57 in moderate response grade, and 101 in mild response grade. According to Becker-TRG system, there were 11 patients in grade 1a, 23 patients in grade 1b, 67 patients in grade 2, and 91 patients in grade 3 (Tables [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}, [4](#Tab4){ref-type="table"}, [5](#Tab5){ref-type="table"} and [6](#Tab6){ref-type="table"}).

Correlation between tumor regression and clinicopathological features {#Sec12}
---------------------------------------------------------------------

Tumor regression evaluated by all the five grading systems has been found significantly associated with histological differentiation, postsurgical T category, postsurgical N category, AJCC stage, LVI, PNI and tumor size (*P* \< 0.05) (Tables [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}, [4](#Tab4){ref-type="table"}, [5](#Tab5){ref-type="table"} and [6](#Tab6){ref-type="table"}).

Survival analysis {#Sec13}
-----------------

One hundred and eighty-one patients were analyzed in survival analysis. At the final follow-up, 81 patients (44.8%) were alive with no evidence of recurrence, while 16 (8.8%) were alive with recurrence. Eighty-three patients (45.9%) had died due to disease recurrence, while 1 (0.5%) had died of unknown reason excluding disease recurrence.

All of the five TRG systems, histological differentiation, postsurgical T category, postsurgical N category, AJCC stage, LVI, PNI, Laurén classification, R0 resection and tumor size were significant (*P* \< 0.05) correlated with OS and PFS in univariate Cox regression analyses (Table [7](#Tab7){ref-type="table"}). The overall and progression-free survival curves of five TRG systems were present in Figs. [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"}, respectively.Table 7Univariate Cox regression analysesCharacteristicsOSPFSHR95% CI*P* valueHR95% CI*P* valueGender Male (reference)11 Female1.1790.740--1.8760.4881.3090.859--1.9940.211Age \< 55y (reference)11 ≥ 55y1.1200.903--1.3900.3030.8560.577--1.2700.441Location Esophagogastric junction (reference)11 Proximal gastric0.9520.555--1.6320.8570.8290.506--1.3580.456 Distal gastric0.6340.360--1.1170.1150.6310.380--1.0460.074Maximal diameter of tumor bed1.7121.275--2.299\<0.0011.7091.304--2.239\<0.001Histological differentiation3.0571.617--5.7820.0012.6671.513--4.6990.001Laurén classification Intestinal (reference)11 Diffuse2.2281.339--3.7090.0021.8961.199--2.9990.006 Mixed2.2061.216--4.0030.0091.9111.113--3.2800.019LVI3.3182.089--5.270\<0.0013.3242.180--5.069\<0.001PNI2.8781.750--4.733\<0.0012.7241.737--4.271\<0.001AJCC ypT category1.8761.457--2.415\<0.0011.7391.396--2.168\<0.001AJCC ypN category1.9461.572--2.408\<0.0011.9181.578--2.330\<0.001AJCC stage2.4841.724--3.580\<0.0012.2701.650--3.122\<0.001Mandard-TRG 1 (reference)11 20.980.244--3.9290.9771.2930.343--4.8770.704 31.9560.568--6.7300.2872.1430.631--7.2830.222 42.7170.836--8.8310.0963.1550.979--10.1680.054 53.6821.094--12.3940.0354.5701.380--15.1320.013JGCA-TRG 3 (reference)11 21.5310.457--5.1260.491.7820.539--5.8920.344 1b2.6260.781--8.8310.1192.6210.786--8.7380.117 1a2.8750.836--9.8840.0944.0221.199--13.4910.024 03.6761.092--12.3710.0354.5561.376--15.0850.013CAP-TRG 0 (reference)11 10.9790.244--3.9270.9771.2920.343--4.8730.705 21.9530.568--6.7190.2882.1400.630--7.2720.223 32.9960.937--9.5860.0643.5581.119--11.3110.032China-TRG Severe response (reference)11 Moderate response1.7190.808--3.6570.1601.6610.834--3.3080.149 Mild response2.8561.450--5.6280.0022.8681.544--5.3280.001Becker-TRG 1a (reference)11 1b0.9800.244--3.9270.9771.2920.343--4.8720.705 22.2160.673--7.2940.1902.2950.702--7.5020.169 33.1090.964--10.0280.0583.9641.239--12.6810.020R0 resection Yes (reference)11 No3.3822.022--5.659\<0.0013.6562.315--5.774\<0.001Adjuvant chemotherapy Not received (reference)11 Received1.0400.633--1.7070.8781.2270.774--1.9430.384 Fig. 1Overall survival curves of five TRG systems, respectively. **a** Mandard-TRG, **b** JGCA-TRG, **c** CAP-TRG, **d** China-TRG and **e** Becker-TRG Fig. 2Progression-free survival curves of five TRG systems, respectively. **a** Mandard-TRG, **b** JGCA-TRG, **c** CAP-TRG, **d** China-TRG and **e** Becker-TRG

Postsurgical T category, postsurgical N category, R0 resection and LVI were independent predictors for OS, while LVI, postsurgical N category and R0 resection were independent predictors for PFS, revealed by backward multivariate Cox regression models (Table [8](#Tab8){ref-type="table"}). None of the five tumor regression grading systems were found statistically significant in multivariate survival analysis. In Mandard-TRG system using univariate Cox analysis, the hazard ratio of no response grade was 3.682 and 4.57 in OS and PFS, respectively. In JGCA-TRG system using univariate Cox analysis, the hazard ratio of no response grade was 3.676 and 4.556 in OS and PFS, respectively (Table [7](#Tab7){ref-type="table"}). In the Kaplan-Meier analysis, the median survival time of OS was 84.4 months for patients with Grade 2 in Mandard-TRG system, and 57.8 months for those with Grade 2 in JGCA-TRG system (Table [9](#Tab9){ref-type="table"}).Table 8Multivariate Cox regression analysesCharacteristicsOSPFSHR95% CI*P* valueHR95% CI*P* valueHistological differentiation\-\--1.6620.914--3.0220.096LVI1.6510.976--2.7930.0621.7661.091--2.8610.021AJCC ypT category1.3551.029--1.7840.031\-\--AJCC ypN category1.4871.168--1.8940.0011.4791.180--1.855\<0.001R0 resection2.3861.398--4.0730.0012.4571.516--3.985\<0.001 Table 9Comparison of median survival time between Mandard-TRG and JGCA-TRGTRG systemsMedian for survival timeOSPFSMandard-TRG 1Not reachedNot reached 284.4Not reached 351.842.4 438.722.1 524.312.8JGCA-TRG 3Not reachedNot reached 257.851.8 1b38.729.3 1a30.89.6 024.312.8

Discussion {#Sec14}
==========

Neoadjuvant and adjuvant therapy have been applied to improve the outcome of localized advanced GC, especially in east Asia \[[@CR11]\]. Preoperative therapy promoted R0 resection rates in some randomized studies \[[@CR12]\]. Although the efficacy of preoperative chemotherapy could be partially reflected by the Response Evaluation Criteria in Solid Tumors (RECIST), RECIST is not always consistent with histopathological regression and prognosis. Thus the relationship among histopathological tumor regression evaluation, efficiency of the multimodality therapy and prognosis requires further illumination. Globally, there have been many kinds of histopathological tumor regression grading systems. Mandard et al. first published their five-tiered TRG system for esophageal carcinoma in 1994. It was reproducible and used widely in carcinomas of esophagus/esophagogastric junction and rectum, but there have been no published applications in GC yet. CAP recommended a simplified four-tiered TRG system based on Mandard-TRG system. In China, a three-tiered grading system is used to assess therapeutic response for solid malignancies. However, its applicability on GC remained unclear. Becker et al. proposed a semi-quantitative four-tiered TRG system in 2003, and then they proved the applicability on GC in 2011. In Japan, the wildly used method to evaluate pathological response is JGCA-TRG, of which the criteria for tumor regression separation are quite distinct from the other four TRG systems.

In this study, 118 (61.4%) patients had mild or minimal tumor regression. Only 11 (5.7%) cases got complete regression without any residual tumor cells on the primary sites, but unfortunately 2 of them were found with residual lymph nodes metastasis, probably resulting in poor outcomes. Twenty-three (12.0%) patients had nearly complete regression with a few residual tumor cells. We supposed the patients who reached complete response should have a better prognosis while the patients who reached nearly complete response should have a worse prognosis. However the actual results did not confirm this. Agoston et al. defined pathological complete response as neither residual primary tumor nor residual lymph node metastasis existing \[[@CR13]\]. They reviewed esophageal adenocarcinoma 93 cases with complete response and found that adequacy of histological examination of the tumor bed affected the prognosis. In our study, the number of tumor blocks ranged from 4 to 53 in the complete response cases, while the number ranged from 5 to 77 in the nearly complete response cases. The fewer blocks of some cases might indicate potentially insufficient tumor sampling. Meanwhile, in some other studies which emphasized on adequacy of gross sampling, the percentage of complete response in GC ranged from 1.2 to 3.6% \[[@CR14]--[@CR16]\]. Among the 23 nearly complete response cases in our study, only 5 were classified to postsurgical T3 or T4 categories, while the others were suspected to have earlier T categories before the preoperative therapy. This could be supposed to explain the different prognosis between patients who reached complete response and the patients who had nearly complete response. It is controversial on whether separating the complete response from the nearly complete response. Becker et al. separated the complete response category from the nearly complete response category and assessed separately, however, they combined them for survival analysis \[[@CR9]\].

Chirieac et al. demonstrated their TRG system as an independent predictor on esophageal and esophagogastric junction cancer. They evaluated the residual tumor semi-quantitatively as 0% residue, 1--50% residue and \>50% residue \[[@CR17]\]. Becker et al. found the significance in multivariate analysis on the proportion of residual tumor between \<10 and \>10% in GC \[[@CR9]\]. Both studies were based on large number of patients and long-term follow-up. On contrary, more studies did not demonstrate the independent role of TRG for prognosis. In our univariate survival analysis, all the five TRG systems showed statistical significance which was coincident with other studies \[[@CR12], [@CR14], [@CR18], [@CR19]\]. We collected exhaustive clinicopathological characteristics to establish the reliability of this study. The results indicated that all the TRG systems tightly correlated with LVI, postsurgical T and N categories, therefore the staging status and LVI would affect the statistical significance of the TRG systems in multivariate survival analysis. This could elucidate the absence of independent significance of the TRG systems. As compared with other grading systems, the hazard ratio of no/slightly response grade in both Mandard-TRG system and JGCA-TRG system revealed higher hazard of death and disease progression than that of severe response grade when using univariate Cox survival analysis. Furthermore, the main difference between the two five-tiered TRG systems is whether separating the category of nearly complete response from partial response. In Mandard-TRG system, the category of nearly complete response is separated, however, in JGCA-TRG system, it is not. Because the median survival time of patients with nearly complete response in Mandard-TRG system (84.4 months) was much longer than those with partial response in JGCA-TRG (57.8 months) (Table [9](#Tab9){ref-type="table"}), separation of nearly complete response and partial response categories in Mandard-TRG system could be more reasonable for prognosis prediction.

Conclusions {#Sec15}
===========

This study analyzed five classic TRG systems on GC after neoadjuvant chemotherapy and revealed the significance of all the five TRG systems in univariate survival analysis. We recommend Mandard-TRG system in GC evaluation for prediction of survival.
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